Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × patritumab deruxtecan × Tumor-Agnostic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 9 Thoracic 8 Gastrointestinal 5 CNS 2 Tumor-Agnostic 1 Other solid neoplasm 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 Dermatologic 1

Conditions

Interventions

pembrolizumab 86 Paclitaxel 78 Gemcitabine 73 Carboplatin 72 Docetaxel 52 Cisplatin 52 Bevacizumab 51 Nivolumab 50 Fluorouracil 43 Capecitabine 43 Magnetic Resonance Spectroscopy 40 Radiotherapy 36 Irinotecan 36 Oxaliplatin 34 Erlotinib Hydrochloride 34 Biopsy 32 Pemetrexed 30 Leucovorin 30 Standard of Care 29 atezolizumab 27 Trastuzumab 27 Blood Specimen Collection 27 Specimen Handling 26 Cetuximab 26 Sorafenib 25 Radiosurgery 25 Everolimus 25 Cyclophosphamide 25 Ipilimumab 22 130-nm albumin-bound paclitaxel 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06941272 2026-03-13

MK-9999-01C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡